Evaluation of systemic Rituximab for treating orbital MALT lymphoma
Not Applicable
Recruiting
- Conditions
- Orbital MALT lymphoma
- Registration Number
- JPRN-UMIN000009512
- Lead Sponsor
- Osaka University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
The patients who have history of myocardial infarction and brain infarction.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method best-corrected visual acuity, intraocular pressure, indirect ophthalmoscopy, and slit-lamp examination before and after every treatment
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Rituximab's efficacy in orbital MALT lymphoma treatment?
How does systemic Rituximab compare to localized therapies for orbital MALT lymphoma outcomes?
Which biomarkers correlate with response to Rituximab in CD20-positive MALT lymphoma subtypes?
What adverse events are associated with long-term Rituximab use in ocular adnexal lymphoma patients?
Are there synergistic effects when combining Rituximab with BTK inhibitors for MALT lymphoma treatment?